113 related articles for article (PubMed ID: 7987825)
1. Mutation rate of the CDKN2 gene in malignant gliomas.
Giani C; Finocchiaro G
Cancer Res; 1994 Dec; 54(24):6338-9. PubMed ID: 7987825
[TBL] [Abstract][Full Text] [Related]
2. Deletion and transfection analysis of the p15/MTS2 gene in malignant gliomas.
Tenan M; Benedetti S; Finocchiaro G
Biochem Biophys Res Commun; 1995 Dec; 217(1):195-202. PubMed ID: 8526910
[TBL] [Abstract][Full Text] [Related]
3. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas.
Fueyo J; Gomez-Manzano C; Bruner JM; Saito Y; Zhang B; Zhang W; Levin VA; Yung WK; Kyritsis AP
Oncogene; 1996 Oct; 13(8):1615-9. PubMed ID: 8895506
[TBL] [Abstract][Full Text] [Related]
5. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
7. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth.
Arap W; Nishikawa R; Furnari FB; Cavenee WK; Huang HJ
Cancer Res; 1995 Mar; 55(6):1351-4. PubMed ID: 7882335
[TBL] [Abstract][Full Text] [Related]
8. [Analysis on point mutation of the CDKN2/p16 gene in lung cancer].
Su C; Ye Y; Wang D; Cao X; Li S; Shan X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):37-40. PubMed ID: 11836684
[TBL] [Abstract][Full Text] [Related]
9. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas.
Xu L; Sgroi D; Sterner CJ; Beauchamp RL; Pinney DM; Keel S; Ueki K; Rutter JL; Buckler AJ; Louis DN
Cancer Res; 1994 Oct; 54(20):5262-4. PubMed ID: 7923151
[TBL] [Abstract][Full Text] [Related]
11. Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines.
Pollock PM; Yu F; Qiu L; Parsons PG; Hayward NK
Oncogene; 1995 Aug; 11(4):663-8. PubMed ID: 7651729
[TBL] [Abstract][Full Text] [Related]
12. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
13. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Fujishita T; Mizushima Y; Kashii T; Kobayashi M
Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
[TBL] [Abstract][Full Text] [Related]
14. p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines.
Hirama T; Miller CW; Wilczynski SP; Koeffler HP
Mod Pathol; 1996 Jan; 9(1):26-31. PubMed ID: 8821952
[TBL] [Abstract][Full Text] [Related]
15. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma.
Maesawa C; Tamura G; Nishizuka S; Ogasawara S; Ishida K; Terashima M; Sakata K; Sato N; Saito K; Satodate R
Cancer Res; 1996 Sep; 56(17):3875-8. PubMed ID: 8752149
[TBL] [Abstract][Full Text] [Related]
17. Mutations of the p16 gene in gliomas.
Kyritsis AP; Zhang B; Zhang W; Xiao M; Takeshima H; Bondy ML; Cunningham JE; Levin VA; Bruner J
Oncogene; 1996 Jan; 12(1):63-7. PubMed ID: 8552400
[TBL] [Abstract][Full Text] [Related]
18. A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer.
Schmid M; Sen M; Rosenbach MD; Carrera CJ; Friedman H; Carson DA
Oncogene; 2000 Nov; 19(50):5747-54. PubMed ID: 11126361
[TBL] [Abstract][Full Text] [Related]
19. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation.
Costello JF; Berger MS; Huang HS; Cavenee WK
Cancer Res; 1996 May; 56(10):2405-10. PubMed ID: 8625319
[TBL] [Abstract][Full Text] [Related]
20. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma.
Iolascon A; Faienza MF; Coppola B; Rosolen A; Basso G; Della Ragione F; Schettini F
Genes Chromosomes Cancer; 1996 Apr; 15(4):217-22. PubMed ID: 8703847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
